Home/Filings/4/0001567619-21-012858
4//SEC Filing

GOODMAN COREY S 4

Accession 0001567619-21-012858

CIK 0001783032other

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 5:27 PM ET

Size

16.0 KB

Accession

0001567619-21-012858

Insider Transaction Report

Form 4
Period: 2021-06-29
Transactions
  • Purchase

    Common Stock

    2021-06-29$16.00/sh+625,000$10,000,0002,608,167 total
  • Conversion

    Series B Preferred Stock

    2021-06-298,380,0340 total
    Common Stock (1,983,167 underlying)
  • Conversion

    Common Stock

    2021-06-29+1,983,1671,983,167 total
Transactions
  • Purchase

    Common Stock

    2021-06-29$16.00/sh+625,000$10,000,0002,608,167 total
  • Conversion

    Common Stock

    2021-06-29+1,983,1671,983,167 total
  • Conversion

    Series B Preferred Stock

    2021-06-298,380,0340 total
    Common Stock (1,983,167 underlying)
Royston Aaron
10% Owner
Transactions
  • Conversion

    Series B Preferred Stock

    2021-06-298,380,0340 total
    Common Stock (1,983,167 underlying)
  • Conversion

    Common Stock

    2021-06-29+1,983,1671,983,167 total
  • Purchase

    Common Stock

    2021-06-29$16.00/sh+625,000$10,000,0002,608,167 total
Transactions
  • Conversion

    Series B Preferred Stock

    2021-06-298,380,0340 total
    Common Stock (1,983,167 underlying)
  • Purchase

    Common Stock

    2021-06-29$16.00/sh+625,000$10,000,0002,608,167 total
  • Conversion

    Common Stock

    2021-06-29+1,983,1671,983,167 total
Transactions
  • Conversion

    Common Stock

    2021-06-29+1,983,1671,983,167 total
  • Conversion

    Series B Preferred Stock

    2021-06-298,380,0340 total
    Common Stock (1,983,167 underlying)
  • Purchase

    Common Stock

    2021-06-29$16.00/sh+625,000$10,000,0002,608,167 total
Footnotes (2)
  • [F1]Each share of Series B Preferred Stock automatically converted into approximately 0.236654 shares of the Issuer's common stock immediately prior to the completion of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
  • [F2]The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.

Documents

1 file

Issuer

Elevation Oncology, Inc.

CIK 0001783032

Entity typeother

Related Parties

1
  • filerCIK 0001278411

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 5:27 PM ET
Size
16.0 KB